BRE expression predicts favorable DFS in radiotherapy-treated patients with small tumors. In radiotherapy-treated patients, BRE expression predicts DFS in patients with small tumors (pT1, upper panel). The 5-year DFS was 72.7 ± 9.5 % and 92.6 ± 4.1 % for low and high BRE expression, respectively (HR = 0.23, CI = 0.068–0.75, p = 0.015). For patients with larger tumors, no statistically significant prognostic effect of BRE expression was observed. For this analysis, patients were subdivided into two groups based on BRE expression, as explained in Fig. 1. p-values, HR’s, and CI’s were calculated by the logrank method